Ionis Pharmaceuticals stock maintains Buy rating at TD Cowen on pipeline strength
PositiveFinancial Markets

Ionis Pharmaceuticals has received a Buy rating from TD Cowen, highlighting the strength of its pipeline. This is significant as it reflects confidence in the company's future growth and potential breakthroughs in drug development, which could lead to improved patient outcomes and increased investor interest.
— Curated by the World Pulse Now AI Editorial System